Literature DB >> 30717515

[Clinical application evaluation and revision suggestions of clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for community acquired pneumonia].

De-Min Li1, Rui-Han Qi1, Hong-Chun Zhang1, Xing Liao2, Yan-Ming Xie2, Jun-Hua Zhang3, Bo-Li Zhang3.   

Abstract

To clarify the clinical application of the group standard (T/CACM 1035-2017) of the Chinese Society of Traditional Chinese Medicine (TCM), the clinical practice guideline on traditional chinese medicine therapy alone or combined with community acquired pneumonia, and to understand the clinical applicability of the Guideline. The clinical workers trained in terms of the Guideline in hospitals at all levels in China were selected as the research objects. A total of 494 questionnaires on application evaluation and 511 questionnaires on applicability evaluation were collected to construct the database of the post-effect evaluation of the Guideline. Excel software was used for statistical analysis. The overall evaluation of the Guideline was 92.31%, 91.06%, 87.45% respectively in efficacy, safety and economy. The Guideline was well used in clinical application, and 99.41% of the patients were willing to follow the recommended scheme. The agreed ratio in rationality evaluation was 97.98%, 92.37%, 94.53% and 92.71% in treatment rules, syndrome differentiation and classification, prevention of complications, and rehabilitation method. The effective rate of the prescriptions recommended in the Guideline was all above 65%. More than 80% of the prescriptions were Tanreqing Injection, Yinqiao Powder, Qingjin Huatan Decoction, Maxing Shigan Decoction, Shengmai San and Shashen Maidong Decoction. Adverse reactions, unknown active components and economy of Chinese patent medicines were the important factors affecting drug use and efficacy, providing a clinical basis for updating and revising the standard. Copyright© by the Chinese Pharmaceutical Association.

Entities:  

Keywords:  Chinese medicine ; Guidelines ; antibiotics ; application evaluation ; clinical applicability ; community acquired pneumonia

Mesh:

Substances:

Year:  2018        PMID: 30717515     DOI: 10.19540/j.cnki.cjcmm.20181009.006

Source DB:  PubMed          Journal:  Zhongguo Zhong Yao Za Zhi        ISSN: 1001-5302


  3 in total

1.  Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial.

Authors:  Yujiao Zheng; Changren Shi; Yaowei Han; Xinmin Li; Lijing Dong; Yan Li; Hui Chen; Yushui Wang; Jinsong Li; Geli Liu; Rong Ma; Fengmei Lian; Xiaolin Tong
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

2.  Shen-ling-bai-zhu-san ameliorates inflammation and lung injury by increasing the gut microbiota in the murine model of Streptococcus pneumonia-induced pneumonia.

Authors:  Jinli Feng; Weibo Dai; Cheng Zhang; Houjun Chen; Ziliang Chen; Yongfeng Chen; Qianyi Pan; Yongmao Zhou
Journal:  BMC Complement Med Ther       Date:  2020-05-27

3.  Effect of traditional Chinese medicine injections on severe pneumonia: A protocol for systematic review and meta-analysis.

Authors:  Wei Luo; Ya Liu; Qiang Zhang; Huifang Zhong; Jia Deng
Journal:  Medicine (Baltimore)       Date:  2020-09-25       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.